Ligand Pharmaceuticals (LGND) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue grew 46% year-over-year to $45.3 million, driven by a 44% increase in royalty revenue and higher Captisol sales, with adjusted EPS up 11% and a net loss of $42.5 million due to a one-time $44.3 million R&D charge.

• Closed strategic transactions including the Pelthos Therapeutics merger and a $75 million royalty financing with Castle Creek Biosciences, expanding the portfolio to over 90 assets.

• Maintains a diversified portfolio with 12 major commercial-stage royalty assets and significant growth drivers like Ohtuvayre, Capvaxive, and Filspari.

• Ended Q1 with $209 million in cash and investments, no debt, and over $400 million in deployable capital including a $125 million credit facility.

• Positioned for continued growth with a five-year royalty receipts CAGR outlook of at least 22%.

Financial highlights

• Q1 2025 total revenue was $45.3 million, up from $31.0 million in Q1 2024, with royalty revenue at $27.5 million, a 44% increase year-over-year.

• Captisol sales were $13.5 million, up from $9.2 million, reflecting increased customer orders and Gilead's Veklury restocking.

• Adjusted EPS was $1.33, up from $1.20 in Q1 2024; core adjusted net income was $26.6 million.

• GAAP net loss of $42.5 million due to a one-time $44.3 million R&D charge and absence of prior year investment gains.

• Operating costs and expenses surged 191% to $81.5 million, primarily from the Castle Creek R&D funding.

Outlook and guidance

• Reaffirmed 2025 guidance: royalty revenue $135–$140 million, Captisol sales $35–$40 million, contract revenue $10–$20 million, total revenue $180–$200 million, and core adjusted EPS $6.00–$6.25.

• Five-year royalty receipts CAGR expected at 22%, with 18% from the current portfolio and at least 4% from future investments.

• Expects continued robust investment activity and EPS growth over 20% through the early 2030s.

• Sufficient liquidity and access to capital are expected to support ongoing operations, investments, and strategic initiatives.

• The Pelthos Therapeutics transaction is expected to close in summer 2025, with ZELSUVMI commercialization as a near-term focus.